Pathology Master Class: Targeting Genomic Alterations for Personalizing Lung and Thyroid Cancer Care

Join us in Chicago or via simulcast for this live, interactive Master Class satellite symposium to get up to date on optimal testing for RET and NTRK alterations in the management of lung and thyroid cancers. A team of oncology pathologists will share their expert guidance on testing strategies for these rare genomic alterations through presentations and small group patient case discussions.

Clinical Care Options, LLC and The American Society for Clinical Pathology are committed to providing a safe and healthy environment for all our learners. Our decisions and preventive measures are guided by the requirements and recommendations of the CDC alongside federal, state, and local health authorities. We work with each program venue to implement preventive measures to reduce the potential spread of COVID-19. In addition, in accordance with ASCP’S COVID-19 protocols, all in-person learners will be asked to wear a mask and present their ASCP conference badge -OR- proof of vaccination* AND government-issued ID to gain admittance to Genomic Alterations in Lung and Thyroid Cancer: Expert Guidance in Incorporating Molecular Testing to Deliver Precision Therapy.

For more information on ASCP’s vaccination and mask requirements, please visit: ASCP’S website

*If you do not have your vaccination record card, find other ways to verify you have been vaccinated.

An official educational opportunity held in conjunction with ASCP 2022 Live + Virtual

Agenda

  • Welcome and Introduction
  • Overview, Rationale, and Guidance on Testing for Rare Genomic Alterations in Advanced Thyroid Cancer – Juan C. Hernandez-Prera, MD
    • RET Fusions or Mutations
    • Testing Strategies for Actionable Genomic Alterations in Thyroid Cancer
  • Overview, Rationale, and Guidance on Testing for Rare Genomic Fusions in NSCLC – Jeremy Segal, MD, PhD
    • NTRK Fusions
    • RET Fusions
    • Testing Strategies for Rare Genomic Fusions in Lung Cancer
  • Master Class Interactive Case Discussions – Faculty Panel
    • Lung Cancer
    • Thyroid Cancer
  • Final Audience Question and Answer Session

Events

Date / Time
Event Details

Faculty

Co-Chair
Juan C. Hernandez-Prera, MD

Associate Member
Department of Pathology
Section Head
Head & Neck - Endocrine Pathology
Department of Pathology
Moffitt Cancer Center
Tampa, Florida

Co-Chair
Jeremy P. Segal, MD, PhD

Faculty
Taylor Bronson, MD

Assistant Professor
Department of Pathology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Faculty
Farres Obeidin, MD

Assistant Professor
Department of Pathology
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Faculty
Peter Sadow, MD, PhD

Associate Professor of Pathology
Harvard Medical School
Director, Head and Neck Pathology
Massachusetts General Hospital
Boston, Massachusetts

Faculty
Melissa Tjota, MD, PhD

Assistant Professor
Department of Pathology
University of Chicago Medical Center
Chicago, Illinois

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and planning individualized treatment for patients with lung or thyroid cancers.

Target Audience
This program is intended for medical oncologists, pathologists, endocrinologists, surgeons, interventional radiologists, and other healthcare professionals who care for patients with lung or thyroid cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Order appropriate assays or molecular tests to detect oncogenic gene fusions in patients with NSCLC and thyroid cancer
  • Appraise emerging clinical data supporting the use of TRK inhibition in NTRK fusion–positive NSCLC and thyroid cancer and RET inhibition in RET-altered lung and thyroid cancer
  • Formulate strategies for integrating TRK and RET inhibitors into the management of eligible patients with NSCLC and thyroid cancer, based on expert recommendations and oncogenic gene fusion status
  • Develop treatment strategies for patients with cancer who develop acquired resistance to first-generation TRK and RET inhibitor therapy
  • Manage treatment-related symptoms associated with the treatment of RET altered or NTRK fusion–positive cancer
  • Refer eligible patients with NTRK fusion–positive and RET-altered NSCLC and thyroid cancer for ongoing clinical trials

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning point in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Provided by Clinical Care Options, LLC

In partnership with American Society for Clinical Pathology

Supported by an educational grant from

Bayer HealthCare Pharmaceuticals Inc.
Blueprint Medicines
Genentech, a member of the Roche Group
Lilly

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.